The Long Return on Discovery Science in Cancer Therapeutics

Many advances in cancer treatment depend on discoveries made decades earlier. In this Comment, Murphy et al. discuss the histories of EGFR, HER2, CDK4/6 and RAS, highlighting how long translation can take and how clinical benefit can continue to accumulate as more effective drugs are developed, used in earlier disease settings and combined with existing treatments.